Mazdutide vs Pemvidutide

Mazdutide and Pemvidutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

Mazdutide (IBI362), a dual GLP-1/glucagon receptor agonist, was co-developed by Innovent Biologics and Eli Lilly, with a molecular weight of 4,563.06 g/mol. This peptide is administered once weekly and works by stimulating both GLP-1 and glucagon receptors. The dual action aims to achieve appetite suppression and improved glucose metabolism through GLP-1, while glucagon activation is expected to enhance energy expenditure and reduce hepatic fat. Notably, Mazdutide received approval from China’s NMPA in June 2025 for chronic weight management and later in September 2025 for glycemic control in type 2 diabetes, marking it as the first of its kind globally. Clinical studies indicate significant weight loss among Chinese adults with obesity and effective glycemic control, alongside reductions in hepatic fat content. However, the evidence is primarily derived from trials conducted in specific populations, necessitating further investigation in diverse demographic groups to confirm its broader applicability.

Pemvidutide (ALT-801) is another dual GLP-1/glucagon receptor agonist, developed by Altimmune, targeting obesity and nonalcoholic steatohepatitis (NASH/MASH). Like Mazdutide, it is designed for once-weekly administration and aims to leverage the appetite-suppressing effects of GLP-1 alongside glucagon's role in increasing energy expenditure and reducing liver fat. Pemvidutide is currently in Phase III development, with preliminary studies suggesting clinically meaningful weight loss in individuals with obesity, alongside substantial reductions in liver fat and preservation of lean body mass. While these findings are promising, they are still emerging, and the full scope of Pemvidutide's efficacy and safety profile will be clearer upon the completion of ongoing clinical trials. The research thus far highlights its potential but also underscores the need for comprehensive evaluations in varied populations to ascertain its effectiveness.

Mazdutide and Pemvidutide are both primarily investigated for their roles in weight management and metabolic health. Their dual-action mechanisms targeting GLP-1 and glucagon receptors position them as promising candidates for addressing obesity and related metabolic disorders. While both peptides share these applications, Mazdutide does not have additional unique research applications reported at this time. Similarly, Pemvidutide's current research focus is limited to obesity and NASH/MASH, with no additional unique applications identified. The shared focus on weight management and metabolic health reflects a broader trend in peptide research aimed at developing effective therapeutic options for these pressing health issues.

The safety profiles of Mazdutide and Pemvidutide reveal commonalities, particularly concerning gastrointestinal (GI) side effects. For Mazdutide, adverse effects such as nausea, vomiting, and diarrhea are frequently reported, akin to those observed with other GLP-1 agonists. These GI events are typically dose-dependent and transient, with an increase in heart rate also noted, consistent with the effects seen in the GLP-1 agonist class. Similarly, Pemvidutide presents a comparable safety profile, with common effects including nausea, vomiting, diarrhea, and decreased appetite. Like Mazdutide, the GI adverse events associated with Pemvidutide are also dose-dependent and generally resolve over time. The shared safety concerns highlight the importance of monitoring these effects in clinical settings, especially as both peptides undergo further evaluation in ongoing trials.